BioNTech's Founders Are Building a New mRNA Company While Their Old One Shrinks to a Cancer Lab

BioNTech will wind down Idar-Oberstein, Marburg and Tübingen sites by 2028, affecting up to 1,860 roles, as it bets on cancer drug Gotistobart.

BioNTech is trading at 87.00 euros as of yesterday's close, up 7.0% year-to-date but 18% below its 52-week high — a muted market verdict on a company that is simultaneously dismantling its industrial base and pinning its future on a single oncology asset.

The Mainz-based biotech confirmed it will wind down manufacturing sites in Idar-Oberstein, Marburg and Tübingen in stages through the end of 2028, after failing to find buyers for the properties. Production of the COVID-19 vaccine shifts entirely to long-time US partner Pfizer. Up to 1,860 positions are affected, with socially acceptable solutions agreed with the works council. Operations in Singapore are also being discontinued.

From Vaccine Factory to Research Shop

The retreat from large-scale manufacturing marks a return to what BioNTech was before the pandemic thrust it into the global spotlight: a research-driven development outfit that channels its capital into clinical trials rather than the upkeep of expensive infrastructure. The sprawling production capacity was a historic necessity during the health crisis, but against today's shrunken demand those halls became a costly burden.

Giving up capital-intensive mass production frees the company from a heavy cost load and curbs its cash burn. What it surrenders in return is a measure of control over its own value chain — a pragmatic but defensive trade that raises the stakes on the remaining pipeline.

A Founder Exit in the Making

The upheaval reaches beyond the factory floor. According to media reports, co-founders U?ur ?ahin and Özlem Türeci have established a new venture called Arife, which will focus on next-generation mRNA medicines. Bloomberg reported the project is set to launch before the end of the year, and both founders are expected to leave BioNTech by the end of 2026.

?ahin's sale of share packages roughly a week ago — executed under a pre-arranged Rule 10b5-1 trading plan, with the stock up 0.5% since — fits the picture of transition, though such transactions naturally stir psychological reservations among investors. The deeper strategic question is whether the organization can evolve from a founder-led exceptional phenomenon into an institutionalized pharmaceutical company. Without the charismatic research duo at the helm, the remaining pipeline must prove it can stand on its own.

Administrative changes are underway as well. About two weeks ago, the supervisory board resolved to propose KPMG AG Wirtschaftsprüfungsgesellschaft as independent auditor to the annual general meeting.

Gotistobart Data Carry the Story

The answer to the future question is being sought in the company's cancer studies. Roughly two weeks ago, BioNTech presented updated Phase 3 data for the antibody Gotistobart, developed in cooperation with OncoC4: median overall survival in pre-treated squamous cell lung carcinoma reached 18.5 months versus 10.0 months on docetaxel chemotherapy. The decisive second stage of this registrational trial is ongoing.

That result is the strongest argument against the skepticism reflected in the share price. The market has rewarded cost discipline only hesitantly, because the growth story still needs proof. Management is shrinking the company back to its researching core, which protects the balance sheet and dampens the burn rate — but new momentum from oncology cannot simply be saved into existence.

BioNTech sits at a decisive threshold. The site closures and the transfer of vaccine production close the chapter on pandemic-era windfall revenues for good. Whether a lean, purely oncology-focused structure ultimately creates the value shareholders hope for will be decided not on the production lines in Hesse or Baden-Württemberg, but in the laboratories and cancer centers. For investors, an era is beginning in which clinical data and study endpoints alone determine the fate of the stock.